Demonstration of differences in colonic volumes, transit, chyme consistency and response to psyllium between healthy and constipated subjects using magnetic resonance imaging by Major, Giles et al.
  
Major 1 
TITLE: Demonstration of differences in colonic volumes, transit, chyme 
consistency and response to psyllium between healthy and constipated 
subjects using Magnetic Resonance Imaging  
 
SHORT TITLE: Demonstration of effects of psyllium using MRI 
 
AUTHORS: Giles Major*1, Kathryn Murray*1,2,  Gulzar Singh1, Adam Nowak1, 
Caroline L. Hoad1,2, Luca Marciani1, Ada Silos-Santiago3, Caroline B. Kurtz3, Jeffrey 
M. Johnston3,  Penny Gowland1,2, and  Robin Spiller1 
*these authors assert joint first authorship.  
 
1. Nottingham Digestive Diseases Centre and National Institute for Health 
Research (NIHR) Nottingham Biomedical Research Centre, Nottingham 
University Hospitals NHS Trust and University of Nottingham, UK  
2. Sir Peter Mansfield Imaging Centre, University of Nottingham UK 
3. Ironwood Pharmaceuticals Inc., Cambridge MA USA at the time of the study 
 
CORRESPONDENCE: Address correspondence to Professor Robin Spiller, NIHR 
Nottingham Biomedical Research Centre, Queen’s Medical Centre, E Floor West 
Block, Nottingham University Hospitals, University of Nottingham, Nottingham NG7 
2UH, UK. Tel: +44 (0) 115 8231090. Fax: +44 (0) 1158231409. E-mail: 
Robin.Spiller@nottingham.ac.uk.  
 
WORD COUNT:  3781 
  
Major 2 
ABBREVIATIONS 
AC Ascending Colon 
ACWC Ascending Colon Water Content 
AUC  Area Under the Curve 
BMI Body Mass Index 
DC Descending Colon 
FC  Functional Constipation 
GI   Gastrointestinal 
IBS-C Constipation-predominant Irritable Bowel Syndrome 
MR Magnetic Resonance 
MRI Magnetic Resonance Imaging 
Q25, Q75 Lower and upper quartile 
SBWC Small bowel water content 
SD Standard Deviation 
TC Transverse Colon 
T1 T1 relaxation time 
T2 T2 relaxation time 
t.d.s. Three times daily 
WAPS24 Weighted Average Position Score at 24 hours 
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ABSTRACT  
Background: In functional gastrointestinal disorders a lack of objective biomarkers 
limits evaluation of underlying mechanisms. We aimed to demonstrate the utility of 
Magnetic Resonance Imaging (MRI) for this task using psyllium, an effective 
constipation treatment, in patients and controls.  
 
Methods: Two crossover studies: 1) adults without constipation (controls, n=9) took 
three treatments in randomised order for 6 days - maltodextrin (placebo), psyllium 
3.5g t.d.s and 7g t.d.s.; 2) adults with chronic constipation (patients, n=20) took 
placebo and psyllium 7g t.d.s. for 6 days. MRI was performed fasting and 
postprandially on day 6. Measurements included small bowel and ascending colon 
water content, colonic volume, transit time and MR relaxometry (T1, T2) to assess 
colonic chyme. Stool water percentage was measured.   
 
Results:  7g psyllium t.d.s. increased fasting colonic volumes in controls from 
median 372mL (IQR 284-601) to 578 mL (IQR 510-882), and in patients from median 
831mL (IQR 745–934) to 1104mL (847–1316), P<0.05). Mean postprandial small 
bowel water was higher in controls and patients after 7g psyllium t.d.s. vs. placebo. 
Whole gut transit was slower in patients than controls (P <0.05). T1 of the 
descending colon chyme (fasting) was lower in patients [213ms, 176–420] than 
controls [440ms, 352–884, P <0.05] on placebo, but increased by 7 g psyllium t.d.s. 
[590ms, 446–1338), P<0.001]. Descending colon T1 correlated with baseline stool 
water content and stool frequency on treatment.   
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Conclusions and Inferences: MRI measurements can objectively demonstrate the 
mode of action of therapy targeting intestinal fluid content in constipation. 
 
Trial Registration Number: www.clinicaltrials.gov NCT01805999, NCT02144376. 
   
Keywords: ispaghula, laxative, relaxometry 
 
KEY POINTS 
 MRI can non-invasively simultaneously assess whole gut transit time, colonic 
volumes and gut content including the composition of chyme, using the 
relaxation times T1 and T2. 
 We show that the volume of the ascending colon and transverse colon is 
increased and the water content of the descending colon reduced in people 
with constipation compared to those with normal bowel habit 
 MRI demonstrated that psyllium, an effective treatment for constipation, 
caused an increase in water in the small bowel, colonic volume and a newly 
identified marker of colonic contents, T1, which correlates with water content 
of stool.  
 Through assessing multiple parameters contributing to constipation in a single 
test, MRI has the potential to provide clinical characterisation of patients 
beyond transit alone, leading to more targeted application of current and novel 
therapies. 
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INTRODUCTION  1 
A major challenge in functional gastrointestinal disorders has been to develop 2 
objective biomarkers that can be used to assess treatments more economically than 3 
symptoms, which typically show very wide variability(1). Assessment of the small 4 
bowel and proximal colon has been particularly difficult owing to its inaccessibility. 5 
Capsule technologies, such as endoluminal image analysis(2) and pH monitoring, 6 
provide some information on motility and transit. Scintigraphy has been extensively 7 
used over the last three decades to show changes in transit through the different 8 
regions of the colon(3). It has correctly predicted efficacy in a range of medications 9 
with different modes of action on bowel function(4). It has shown acceleration of 10 
transit in constipation by stimulant laxatives such as bisacodyl(5) and secretogogues 11 
such as lubiprostone(6) however it cannot directly demonstrate whether any effects 12 
are due to changes in the balance of absorption/ secretion of fluid from the lumen or 13 
changes in motility(7).  Transit has been shown to account for 19-27% of the 14 
variance in stool form(3) indicating that there are other important parameters in 15 
predicting bowel function that may be measurable.  16 
 Up to 10L/ day of fluids move into, through and out of the gut lumen(8) but 17 
objectively measuring this is difficult and requires intestinal intubation which, as we 18 
and others have shown, alters fluid volumes significantly(9). Disorders of fecal water 19 
content and/ or bowel habit, either diarrhoea or constipation, may result from an 20 
imbalance of secretion/ absorption rather than just abnormal motor function. 21 
Recently a number of new treatments for constipation stimulating intestinal water 22 
secretion have been introduced (10, 11) but assessment of the resulting changes in 23 
intestinal fluid content has not previously been possible.  24 
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We believe this deficit could be corrected using magnetic resonance imaging (MRI) 25 
based methods to characterise the contents of patients’ small bowel  and colon, and 26 
to measure whole gut transit time as previously described (12-15). We have also 27 
used the relaxation times T1 and T2 to characterise luminal contents (16, 17). T1 28 
and T2 are the time constants with which the magnetization of material in the 29 
scanner returns to baseline after excitation by the radiofrequency pulse.  They are 30 
sensitive to the physical and chemical environment of the water protons via 31 
interactions with surrounding molecules and in the context of colonic chyme, are 32 
expected to fall with a reduction of water associated with more solid chyme.  33 
The aim of these studies was to assess the value of these MRI biomarkers by 34 
investigating their responsiveness to a well characterised laxative, psyllium husk 35 
(ispaghula). Its water-holding properties are known to increase fecal water content 36 
and 24-hour fecal weight but reports of its effect on whole gut transit time are 37 
inconsistent(18, 19). In some patients it produces unacceptable bloating but whether 38 
this reflects distension of intestinal lumen was uncertain.  39 
We present two studies, investigating the MRI changes induced by psyllium in 40 
healthy volunteers, without constipation, and in patients with constipation.  Our 41 
hypotheses were that MRI could detect an increase in small bowel water content 42 
caused by psyllium preventing water absorption.  Furthermore, as this “trapped” 43 
water enters the colon, colonic water content would increase. 44 
 45 
MATERIALS AND METHODS 46 
Study Design 47 
Two studies were conducted: study 1, performed first, recruited adults without GI 48 
disorders (controls); study 2, using similar methodology (see below), recruited adults 49 
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with chronic constipation (patients). Both were designed as placebo-controlled 50 
crossover studies and were conducted according to Good Clinical Practice as 51 
determined by the declaration of Helsinki. All authors had access to the study data, 52 
and reviewed and approved the final manuscript. The protocols were approved by 53 
institutional and national review boards respectively, and prospectively registered on 54 
www.clinicaltrials.gov (NCT01805999 and NCT02144376). All subjects gave written 55 
informed consent. 56 
 57 
In study 1 three treatments were taken in random order: a placebo (maltodextrin) 58 
and two different doses of psyllium. Treatments were separated by washout periods 59 
of one week. Investigators were blind to the order of intervention. The patient study, 60 
study 2, was designed to be less burdensome and so used only two treatments: 61 
placebo and high dose psyllium. In order to ensure return to baseline and avoid any 62 
carryover effect from previous treatment in the patient group, both treatment periods 63 
were preceded by ≥10 days of usual laxative use, then 8 days without laxatives other 64 
than rescue therapy.  Rescue therapy (oral bisacodyl 5mg) was permitted in patients 65 
who had not opened their bowels for 3 days and were experiencing distressing 66 
symptoms, but not in the 48 hours before MRI scans.  67 
 68 
Study Populations 69 
Controls were recruited through general advertisement between May and August 70 
2013. Non-smokers aged 18–65 with BMI 18–30 kg·m-2 were eligible. Exclusion 71 
criteria included: any given history of GI disease or surgery; antibiotic or probiotic 72 
use in the 4 weeks before the study; heavy alcohol intake; pregnancy; lactation; 73 
excessive exercise; inability to discontinue medicines likely to alter gastrointestinal 74 
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transit. Patients were recruited between March 2014 and January 2015 through 75 
hospital clinics and advertisement. Eligibility criteria included age ≥18 and a 76 
diagnosis of chronic constipation, defined as meeting Rome III criteria for either 77 
functional constipation (FC) or constipation-predominant irritable bowel syndrome 78 
(IBS-C). Subjects had to pass at least one bowel motion weekly on usual laxatives. 79 
Exclusion criteria in addition to those for the control study were: use of morphine or 80 
similar opioids; use of open-label psyllium; inability to cease regular laxative use. 81 
Patients also underwent a screening period of 2 weeks off laxatives to document 82 
normal bowel habit. 83 
  84 
Treatments and Procedures (Figure 1) 85 
The active treatment used was Metamucil Original Coarse Fiber (P&G, Cambridge 86 
MA USA), a powder containing approximately 3.4g psyllium per 7 g product. 87 
Maltodextrin (The Hut Group, Northwich UK) was used as the placebo control. 88 
Subjects took 14g of powder three times daily (t.d.s.), either 14 g maltodextrin, 14 89 
gm Metamucil (providing 7g psyllium), or a 50:50 mixture 7 g maltodextrin and 7 g 90 
Metamucil (providing 3.5g psyllium) , each dose taken with 250mL water. Henceforth 91 
in the text we refer to the psyllium doses by their psyllium content i.e. 3.5 or 7 g. 92 
Blinding of subjects and investigators was ensured by providing the powders in 93 
opaque containers, labelled by independent staff and provided in sealed bags so 94 
they could not be recognised. The treatment allocation was according to a computer 95 
generated randomisation code. Investigators were blind to the intervention. Subjects 96 
were not told which intervention they were taking in any treatment period, although 97 
powders did differ subtly in appearance and texture.  98 
 99 
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In each treatment period subjects took the powder for 6 days. Subjects measured 100 
out their doses using a plastic spoon and kept a diary of their treatment compliance. 101 
Compliance was also assessed by measurement of the total weight of powder 102 
consumed, expressed as a % of that expected if compliance was complete. 103 
Compliance of 60% was considered acceptable as >12g psyllium daily would be 104 
expected to exert some effect. Subjects kept a daily diary of abdominal symptoms 105 
and bowel habit.  106 
 107 
On the morning of treatment day 5, subjects swallowed five identical transit markers: 108 
cylinder-shaped inert capsules containing 0.4mL 15µM gadoteric acid, a positive MRI 109 
contrast agent(15). Ingestion was confirmed in patients by direct observation or via a 110 
time-stamped video. On day 6 all subjects attended at 8am, fasted. After an initial 111 
MRI scan, during which the intra-luminal position of the transit markers was 112 
documented, subjects consumed their morning dose followed by a 330kcal standard 113 
rice pudding meal(15, 20). Scans were taken at hourly intervals for 7 hours. Doses of 114 
psyllium/ placebo were repeated 165min and 320min after the meal. A second 1000 115 
kcal meal was consumed before the final scan. Subjects were scanned supine. 116 
Images were acquired using a 1.5T scanner (Achieva, Philips Medical System, Best, 117 
The Netherlands). All MRI parameters were measured during a single 15 minute 118 
episode in the scanner at each time point. Full details of the MRI methodology are 119 
given in the supplementary appendix. 120 
 121 
In the control study, fecal samples for measurement of stool water were taken at 122 
enrolment and after the final MRI scan of each treatment period. Patient samples 123 
were collected during the run-in period without laxatives before each treatment, and 124 
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after at least 72h of treatment. Bisacodyl rescue therapy was not permitted in the 48 125 
hours prior to MRI scanning.  126 
 127 
Endpoints 128 
All endpoints were MRI parameters unless reported otherwise. In the control study 129 
the primary endpoint was ascending colon free water content (ACWC). Secondary 130 
endpoints included: small bowel free water content (SBWC); colonic volume, defined 131 
as the sum of the segmental volumes of the ascending, transverse and descending 132 
colon (AC, TC, DC); the weighted average position score of the transit markers at 133 
24h (WAPS24). This was calculated using the formula (sum of the segment number 134 
X the number of markers in each segment divided by the total number of segments) 135 
as described previously(15) such that a higher score denotes slower whole gut 136 
transit. 137 
 138 
Relaxation times (T1 and T2) of the chyme in the AC and DC were also measured.  139 
T1 (longitudinal relaxation time) depends upon the mobility of the water molecules as 140 
does T2 (transverse relaxation time) which also depends on exchange between 141 
water molecules and surrounding macromolecules. Therefore both of these 142 
parameters are expected to decrease as the colonic content becomes more solid. 143 
Percentage fecal water content was also determined by freeze drying the stool. 144 
Symptoms of flatulence, bloating, abdominal pain and diarrhoea were monitored 145 
between MRI scans using 0-100 visual analogue scales(21). 146 
 147 
In the patient study, the primary endpoint was the weighted average position score of 148 
the transit markers at 24h (WAPS24). Secondary endpoints included SBWC, ACWC, 149 
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colonic volume, T1 and T2 of the colonic chyme, and percentage fecal water content. 150 
Stool diaries were kept for the period off laxatives immediately before each treatment 151 
and during the treatment itself.  152 
 153 
Sample size and Statistical analysis 154 
Sample size calculation for the control study was based on pilot data in healthy 155 
volunteers from a previous study of ACWC(13). Nine subjects would be required in a 156 
crossover design to detect an increase in post prandial area under the curve (AUC) 157 
of ACWC of 15 L.min (an increase of approximately 10%) with 90% power and 158 
P<0.01. To allow for withdrawal and noncompliance, 16 subjects were recruited. In 159 
the patient study the primary endpoint was WAPS24 since we had pilot data on this 160 
endpoint in a relevant patient group by which to power our study. We found, using 161 
our MRI marker method, a transit time of mean (SD) 69.2 (32.6) hours in IBS-C(22). 162 
We calculated that a study with 20 subjects would have 80% power to detect a 163 
change of 21 hours or 30% which is similar to the changes previously reported in 164 
constipated subjects treated with psyllium (23, 24) and judged to represent a minimal 165 
clinically significant difference. 24 subjects were recruited to allow for attrition.  166 
 167 
Fasting parameters were compared between treatments. Postprandial endpoints 168 
were compared using AUC. Data are presented as median (interquartile range) or 169 
mean (SD). Paired differences were assessed for normality using the Shapiro-Wilk 170 
test. 1-way ANOVA with post-hoc Tukey’s multiple comparisons test or 1-way 171 
Friedman’s test followed by Dunn’s multiple comparison test were also carried out 172 
when appropriate. Data are presented as median (interquartile range) or mean 173 
(SD).  For controls, only subjects with data from all treatment periods are 174 
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presented. For patients, an intention-to-treat analysis is reported, taking data from 175 
subjects who had at least one MRI parameter measured. This analyses the first 176 
treatment period of the crossover study only, as if in a parallel group trial, using 177 
Mann-Whitney tests. We also report paired analysis of the patient study in those 178 
subjects who completed both treatment periods.  All comparisons were made by 179 
paired t-test unless otherwise stated where paired differences were non-parametric. 180 
Statistical analyses were carried out using Prism 6 (GraphPad Software Inc., San 181 
Diego, CA, USA) or SPSS version 24 (IBM Corp., Armonk, NY, USA). 182 
 183 
RESULTS 184 
The demographics of subjects are shown in the Supplementary Appendix. 16 control 185 
subjects were randomised and completed the study. Of these, 10 showed adequate 186 
compliance. A scanner failure meant that data for one of these were not available so 187 
data from only 9 subjects are presented. 37 patients consented, of whom 24 passed 188 
screening and were randomised. 4 withdrew before scanning; 4 more withdrew 189 
between treatment periods 1 and 2. 20 patients had at least one MRI scan, 190 
completing one treatment period (11 psyllium; 9 placebo) and were included in the 191 
intention-to-treat analysis (ITT); 16 patients completed both treatment periods with 192 
appropriate compliance and were included in the paired analysis (Supplementary 193 
Table 1). 15 met Rome III criteria for FC and 1 for IBS-C. Fasting and postprandial 194 
results are given in Tables 1 and 2 respectively.  195 
Table 1: Variables measured on fasting MRI after 5 days treatment 196 
Table 2: Area Under the Curve of variables measured on postprandial MRI 197 
scans during day 6 of treatment 198 
 199 
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Outcomes assessed on fasting scans (Table 1) 200 
On fasting scans, psyllium treatment did not lead to detectable differences from 201 
placebo (maltodextrin) in small bowel water content (SBWC) in either study. In the 202 
ITT analysis of patients fasting SBWC was 33mL (IQR 9 – 90) on placebo and 54mL 203 
(24 – 77) on psyllium Figure 2A & 2B show fasting and post-prandial SBWC for the 204 
paired data , Little ascending colon water content (ACWC) was detected with either 205 
treatment in either study: one control and one patient had >5 mL detectable on a 206 
fasting scan after 5 days of placebo compared to 4/9 (controls) and 4/18 (patients) 207 
with >5mL detectable after 5 days of 7 g psyllium t.d.s. In controls, no differences in 208 
WAPS24 transit scores between treatments were detected as after 24 hours most 209 
markers had passed to the rectosigmoid or been expelled. In the patient study 210 
however, where transit was the primary endpoint, scores tended to decrease, 211 
indicating faster transit. In the ITT analysis WAPS24 fell from median 4.2 (3.2 – 5.3) 212 
on placebo to median 2.0 (1.5 – 4.0) after psyllium (P=0.067). In the paired analysis 213 
(n = 16) there was a a mean reduction of 0.8, 95% CI -0.2 to 1.7), a difference that 214 
was not statistically significant (figure 2C).  215 
Figure 2D shows fasting colonic volumes for controls and patients. In controls, both 216 
psyllium doses increased fasting volume: 7 g t.d.s led to mean 53% increase (220 217 
mL, 95% CI 127 – 312). In patients, ITT analysis showed that the colonic volume 218 
increased from 831mL (745 – 934) on placebo to 1104mL (847 – 1316), P<0.05). In 219 
the paired analysis the 7 g t.d.s. dose led to mean within-individual increase of 43% 220 
(332mL, 95% CI 214 – 451). No difference in segmental colonic volumes in patients 221 
was detected in the ITT analysis but in paired analysis both controls and patients 222 
showed a significant increase in the fasting AC and transverse colon (TC), with a 223 
significant increase in the fasting descending colon (DC) also found in patients(Table 224 
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1). Figure 3 illustrates the changes in the ascending colon that were visible on 225 
anatomical scans and water content sequences. 226 
 227 
Fasting data on T1 relaxation times, where higher values would be expected to 228 
reflect increased water content, are shown in Figure 4. In controls, treatment tended 229 
to increase fasting T1 in the AC and DC (Figure 4A) but these differences were not 230 
significant in the ITT analysis. In patients, T1DC was significantly higher in the DC 231 
after psyllium (590ms, 446 – 1338) than placebo (213ms, 176 – 420), P<0.001. 232 
Within-individual comparisons of paired data found higher T1 values after psyllium in 233 
both AC (P<0.05) and DC (P<0.01). Fasting T2 measurements varied widely in 234 
controls without demonstrable difference while differences identified in patients were 235 
not consistent across ITT and paired analyses.  236 
 237 
Outcomes assessed on serial postprandial scans (Table 2) 238 
Postprandial SBWC showed significant differences between treatments for both 239 
groups (Figure 2A & 2B). A dose-response relationship was evident in controls, 240 
where postprandial AUC [change from baseline] psyllium 3.5 g t.d.s. led to an 241 
increase in postprandial SBWC compared to placebo (P<0.01), albeit less 242 
pronounced than that seen with 7 g t.d.s. (P<0.01 versus placebo). An increase with 243 
treatment compared to placebo was equally apparent in patients: median AUC for 244 
SBWC rose from 13.2 L.min (7.2 – 24.3) with placebo to 42.8L.min (24. – 49.1) with 245 
psyllium (P<0.05), with similar values seen in the paired analysis. In our previous 246 
work we described a fall in SBWC in the period 0-90 minutes after the test meal(20) 247 
but this did not occur with 7 g psyllium t.d.s. After the second meal of the study, 248 
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between 360 and 420 minutes, a fall in SBWC was seen with all treatments in both 249 
studies. 250 
 251 
Ascending colon water content (ACWC) in the control study, where it was the 252 
designated primary endpoint, was significant greater in the postprandial phase after 253 
7 g psyllium t.d.s. than placebo (P <0.0001), with a clear dose-response relationship 254 
(P <0.001, Table 2). In patients, postprandial ACWC was undetectable in most 255 
subjects taking placebo, with only 3 volumes >5mL recorded at any point. In this 256 
group AUC for postprandial change in ACWC was greater with psyllium (P <0.05) but 257 
highly variable, with mean postprandial ACWC ranging from 0 – 57 mL, equivalent to 258 
5-10% of colonic volume. Of note, postprandial colonic volumes did not change 259 
significantly from fasting baseline with any treatment in either study.  260 
 261 
Relaxation Times T1 and T2  262 
The AUC [change from baseline] for postprandial T1AC was greater with psyllium in 263 
both regions in both groups(Table 2). Figures 4B (controls) and 4C (patients) show 264 
the postprandial time course for T1AC. The curves for 7 g psyllium t.d.s. show a 265 
postprandial increase that returns to fasting levels after 6 hours. A second rise then 266 
follows the second challenge meal. These rises did not occur with placebo, nor did 267 
T1DC demonstrate such a curve. AUC for patients’ T1DC was higher in the ITT 268 
analysis but not significant so, although values were significantly greater than 269 
placebo in the paired analysis of patients, which was also true for controls taking 7g 270 
t.d.s. psyllium.The AUC [change from baseline] for postprandial T2AC was higher 271 
after both psyllium doses than placebo in controls, and also higher after psyllium in 272 
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patients in the paired analysis. Post-prandial T2DC was only found to be higher in 273 
patients on paired analysis (Supplementary Table 1).   274 
 275 
Fecal Water, Bowel Habit and Symptoms 276 
In controls, stool % water content was not higher after placebo treatment than at 277 
baseline (baseline median 72%, IQR 69 - 73 vs 73%, 69 – 77 on placebo, P=NSig 278 
Wilcoxon). Stool % water was higher than baseline after both psyllium 3.5 g t.d.s. 279 
(median 76%, 68 – 80, P<0.05 Wilcoxon) and psyllium 7 g t.d.s. (81%, 75 – 87, 280 
P<0.05 Wilcoxon). In patients, stool % water was no different at the start of the 281 
placebo and psyllium treatments: 66% (59 – 75) vs. 63% (60 – 70). In this group 282 
psyllium 7 g t.d.s increased stool % water by mean 6.2% (SD7.2, P<0.01, paired t-283 
test) but there was no change after placebo (mean decrease 0.2%, SD10.0).  284 
 285 
In the patient study stool frequency was similar during pre-treatment periods off 286 
laxatives and while taking placebo, but higher while taking psyllium (P <0.05 287 
Wilcoxon, Figure 5A). Mean (SD) stool form (Bristol Stool Form Scale) on psyllium 288 
was 3.5 (0.83) and 2.6 (1.3) on placebo (P =0.07 Wilcoxon, Figure 5B).  289 
 290 
Differences between controls and patients 291 
Fasting scans showed a number of differences between controls and patients (Table 292 
1). WAPS24 scores were greater for patients than controls, indicating slower transit 293 
as expected (Figure 2D). On placebo, fasting colon volumes were larger in patients 294 
than controls (median 745 mL, IQR 455 – 844 vs. 372, 284 – 601 P <0.05). 295 
Differences were primarily due to larger AC and TC in patients. Fasting T1 of chyme 296 
in both the AC and DC was shorter in patients than controls after placebo (both P 297 
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<0.05, Figure 4A). After psyllium, values in patients approached those seen in 298 
controls on placebo.  299 
Comparison of postprandial scans suggested differences between controls and 300 
patients in their small bowel responses. Mean SBWC in the postprandial period (0-301 
420 minutes) in controls was 57 33 mL on placebo, rising to 106 74 mL on 3.5 g 302 
psyllium  t.d.s. and 147 78 mL on 7 g t.d.s. (Friedman’s P <0.001).  In comparison, 303 
patients on placebo had a mean postprandial SBWC of 33 17 mL, rising to 81 41 304 
mL on 7 g psyllium t.d.s. (P <0.001). 305 
 306 
Correlation of relaxometry with fecal water and symptoms 307 
Post hoc analysis of the combined data set for controls and patients showed a 308 
correlation between fecal water content and fasting T1DC after placebo treatment 309 
(figure 6A; Pearson’s r = 0.65, P<0.001 two-tailed). Fasting T1DC also correlated with 310 
stool frequency on treatment (Figure 6B; Pearson’s r = 0.53, P <0.05 two tailed). 311 
 312 
Controls reported minimal symptoms during the study days. In patients, scores were 313 
also low, although fasting scores for bloating were higher after psyllium than placebo 314 
(median 5, 0 – 27 vs. 1.5, 0 - 8, P<0.05 Wilcoxon) and remained higher throughout 315 
the day.   316 
 317 
DISCUSSION 318 
By assessing baseline MRI parameters in healthy volunteers and in patients with 319 
constipation, and demonstrating their responsiveness to psyllium therapy, our study 320 
has not only demonstrated the value of MRI but also revealed some new findings 321 
about constipation. The clinical use of psyllium is based on its capacity to bind water, 322 
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preventing absorption from the lumen. Consistent with this, postprandial small bowel 323 
water increased with psyllium in both patients and controls. It is worth noting that 324 
such a validated, non-invasive test may provide more representative data than older 325 
methods requiring aspiration of a non-absorbable marker as the aspiration catheter 326 
itself may stimulate intestinal activity, causing changes in absorption or secretion (9, 327 
25).  328 
 329 
Volume measurements demonstrated the bulking effect of psyllium. The increases 330 
seen exceeded our expectations, in some cases doubling fasting colonic volume, 331 
which may explain the bloating that some patients experience. Similar substantial 332 
increases in colonic volumes as assessed by MRI have been recently reported in 333 
response to high fibre diets by others (26).  334 
 335 
By trapping water, the psyllium appears to abolish the immediate fall in SBWC 336 
caused by the rapid absorption of sucrose, glucose and water we have previously 337 
observed using the same test meal (20). The fall in SBWC after the second large 338 
1000 kcal meal has been observed in most of our previous studies and we believe 339 
this reflects the gastro-ileal response to feeding as described previously (27, 28).   340 
 341 
We were unable to confirm an effect of psyllium on transit time although there was a 342 
numerical decrease in transit scores in constipated patients. These findings are 343 
consistent with other studies of psyllium where its effect on transit is small or non-344 
significant (18, 19, 23, 24). The increase in colonic volume offers an alternative 345 
explanation for how psyllium increases stool frequency since there is a greater mass 346 
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of stool to pass. Total flow (mass/ time) as assessed by daily stool output may, 347 
therefore, increase despite little change in speed through the gut (distance/ time).      348 
 349 
Psyllium’s main benefit may be through increased water content of colonic chyme 350 
and stool, making feces softer and hence easier to pass. Free water was more 351 
readily detected in the ascending colon of controls, and in both groups after psyllium, 352 
but in individual patients it was often undetectable. This may have resulted from avid 353 
water absorption in the constipated colon, or mixing of free water into the colonic 354 
contents where the MRI signal of the water gets quickly reduced by interactions with 355 
bacteria and tiny pockets of gas from fermentation.  356 
 357 
A major finding in this study was the demonstration of the value of T1 in assessing 358 
colon contents. This has not been previously reported. While free water was only 359 
detectable in a few cases, the parameter T1, reflecting the physical and chemical 360 
environment of the water molecules, was readily measurable in all subjects and 361 
normally distributed. T1 largely reflects the freedom of water molecules to move so 362 
higher values should reflect increased water content of the chyme, as we have 363 
shown previously with Moviprep(16). This is borne out by our observations: values in 364 
the colon were greater proximally than distally, consistent with progressive water 365 
absorption during transit; values were lower in constipation than health but increased 366 
with psyllium, supporting the mechanism of action of psyllium as currently 367 
understood, and again suggesting that free water was mixed with the colonic 368 
contents. Further evidence for this effect is the postprandial rise in T1 seen in the 369 
ascending colon with psyllium during the study day. The increase in T1 seen is 370 
consistent with delivery into the colon of small bowel water that was prevented from 371 
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absorption by the presence of the fibre. Such an effect was not seen in the 372 
descending colon, being further removed from episodic influxes associated with 373 
feeding.  374 
 375 
The correlation of T1 in the descending colon with both fecal water content and stool 376 
frequency supports the clinical relevance of the parameter. Many patients define 377 
their constipation by straining to pass hard, dry stools. Fecal water content can be 378 
measured directly but provides no information on changes more proximally in the 379 
colon. T1 provides a potential method to assess fecal consistency in vivo, and to act 380 
as a non-invasive parameter for evaluation of constipation therapies. The fact that 381 
ascending colon T1 is decreased shows that the dehydration in constipation is found 382 
not only in the stool but throughout the colon. This is concordant with earlier studies 383 
reporting slow orocaecal transit in constipation pointing to an important role for the 384 
small bowel in constipation(29).  385 
A major limitation of MRI has been expense compared with scintigraphy which has 386 
an established track record of evaluation of a range of drugs designed to treat 387 
functional gastrointestinal disorders. However, as we show here, MRI does provide 388 
extra information on mode of action, particularly the impact on regional volumes and 389 
fluid distribution which can only be inferred from changes in transit. This will be of 390 
particular value in evaluating agents with novel modes of action like Tenapanor(30, 391 
31), an inhibitor of the sodium-proton exchanger NHE3, or plant derived inhibitors of 392 
aquaporins like rhein(32). 393 
Our study had limitations. Scanner failure and subject withdrawal reduced our 394 
numbers. Drop outs always raise the concern of selection so we report analysis of 395 
those 20 who completed the first arm of the cross-over as an ITT analysis. We also 396 
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performed a paired analysis limited to those who completed the protocol and on 397 
whom we had adequate scans; supplementary data tables provide these results. 398 
Reassuringly we find very similar results in the paired analysis to the ITT analysis 399 
suggesting that drop out was random and not a source of bias. Sample sizes were 400 
hence small, limiting statistical confidence, but our data will enable more accurate 401 
power calculations for future studies. Heterogeneity in response and variation in 402 
dietary fibre intake may have obscured a treatment effect. Comparisons between the 403 
studies may be affected by differences in age and gender since controls were 404 
younger and predominantly male, while patients were mainly female. In a previous 405 
study increased height was associated with larger colons, suggesting larger colons 406 
in men, although height-standardised colons in women were larger(12). More data 407 
will be needed to understand the impact of age and gender compared to other 408 
physiological factors.  409 
 410 
One advantage of the crossover designs used, and therefore reason to report both 411 
ITT and paired analyses, is the reduction of such sources of variation in assessment 412 
of an intervention’s effect. Such a design is less practical for trials where symptoms 413 
are the primary endpoint as establishment of a symptom pattern generally takes 414 
time. An objective point metric, such as volume or chyme T1, avoids this delay in 415 
assessment and so allows shorter periods of intervention and washout.  416 
 417 
There may have been other opportunities to introduce bias: blinding was imperfect 418 
due to the nature of the intervention and compliance cannot not be guaranteed 419 
without direct observation. These issues are readily addressable with pharmaceutical 420 
therapies where plasma drug concentrations can be measured. The objective nature 421 
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of MRI outcomes somewhat mitigated these issues compared to other methods of 422 
assessing treatment efficacy particularly since MRI analysis was undertaken by a 423 
single operator (KAM) to reduce variation. Our previous work on intra-observer 424 
variation in colonic volume measurement found a coefficient of variation <5%. 425 
Fasting SBWC values were lower than we observed previously (13, 20) which may 426 
be a result of our small sample size here.  427 
 428 
In a short scanning session we assessed fasting volume, relaxation times and 429 
transit. Transit itself reflects the composite effects of propulsive forces, volume of 430 
material and resistance to flow. The two patients with the longest T1AC both had a 431 
transit score in the normal range, and may have a different aetiology for their 432 
symptoms that would respond to different treatment. High scores for bloating and 433 
flatulence during the psyllium study day, but not during the placebo day, were also 434 
seen. Objective assessment of physiological changes offers the chance to further 435 
separate out disorders of the defecatory process from visceral hypersensitivity, as 436 
set out in the Rome IV criteria(1). The prospect of assessing, and predicting, 437 
response to therapy with a single MRI may be enhanced further by developments 438 
such as assessment of colonic wall motion through cine MRI(33, 34).  439 
 440 
These techniques require further validation in larger cohorts and randomised 441 
controlled trials. Nevertheless, this work clearly demonstrates the potential of a 442 
comprehensive MRI panel to measure objective differences in luminal content 443 
between controls and patients with chronic constipation, both in their natural state 444 
and in response to therapeutic modulation. This might be of particular value in 445 
demonstrating the site of action of secretogogues now being introduced into therapy.  446 
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The application of MRI has the potential to generate new insights into intestinal 447 
function, provide a platform for early phase evaluation of new treatments and provide 448 
an objective approach to evaluation of patients with functional disorders not 449 
responding to simple empirical therapy. 450 
  451 
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 598 
SUPPORTING INFORMATION 599 
Study 1 CONSORT diagram 600 
 601 
 602 
 603 
  604 
Excluded  (n=0) 
Did not complete protocol (n = 2) 
 Scanner malfunction (n =2) 
 Lost to follow-up (n=0) 
Allocated to intervention (n=16) 
 Received allocated intervention (n=16) 
Analysed  (n=14)  
 Compliance Breach (n=5) 
9 included in per protocol analysis 
Allocation 
Analysis 
Follow-Up 
Enrolment 
Assessed for eligibility (n=16) 
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Study 2 CONSORT diagram 605 
 606 
 607 
 608 
 609 
 610 
 611 
  612 
Assessed for eligibility (n=37) 
Excluded (n=13) 
   Not meeting inclusion criteria (n= 8) 
   Other reasons (personal, difficulty in 
scheduling study days, n=5) 
Did not complete protocol (n = 8) 
 Withdrawal (n=2):  1 change in circumstances;  
1 due to adverse event [nausea] 
 Dropout (n=3):  2 after 1st period; 1 after 2nd period 
 Withdrawn (n=3):  3 MRI scanner failure [2nd period] 
Allocated to intervention (n=24) 
 Received allocated intervention (n=24) 
ITT Analysis (n=20: 9 placebo; 11 psyllium) 
Paired Analysis(n=16)  
Compliance Breach (n=0) 
Allocation 
Analysis 
Follow-Up 
Enrolment 
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Demographics of Participants 613 
 614 
Median and interquartile 
range (Q25 – Q75) 
Study 1: 
CONTROLS 
Study 2:  
PATIENTS 
Age 23.5 (21.25 – 25) 39 (26 – 47.5) 
Gender (M:F) 12 : 4 2 : 22 
Body Mass Index (kg.m-2) 22.5 (21.2 – 25.3) 25.9 (21.4 – 28.8) 
Current smoker (Y:N) 0 : 16 6 : 18 
HADS Anxiety Score 
(normal <8) 
4 (2.25 – 5.75) 4.5 (3 – 6.75) 
HADS Depression Score 
(normal <8) 
1 (0 – 1.75) 2 (0 – 4.75) 
Patient Health 
Questionnaire 
(PHQ-12) 
2 (1 – 3)  3.5 (1 – 6.5) 
 615 
  616 
  
Major 33 
MRI protocol and analysis  617 
 618 
All images were acquired using a whole-body 1.5T scanner (Achieva, Philips Medical 619 
System, Best, The Netherlands). Each imaging period lasted for 15 – 20 minutes and 620 
volunteers were positioned supine in the magnet with a 16-element receiver coil 621 
wrapped around the abdominal region. Between scans, patients and volunteers were 622 
asked to sit upright away from the scanner.  623 
 624 
The volume of freely mobile water in the small bowel (Small Bowel Water Content, 625 
SBWC) was measured and analysed as described previously (1) using a coronal 626 
single-shot turbo spin-echo sequence, acquiring 24 slices in a single 24 second 627 
breath hold (TR/TEeff = 8000/320 ms, 512x512 reconstructed matrix, reconstructed 628 
voxel size 0.78x0.78x7 mm3). Ascending colon water content (ACWC) was 629 
measured and analysed similarly.  Colonic volume measurements, as described in 630 
detail previously (1, 2), were obtained using a coronal dual-echo gradient echo 631 
sequence (TR/TE1/TE2 = 157/2.3/4.6 ms, 256x256 reconstructed matrix, 632 
reconstructed voxel size1.76x1.76x7 mm3).  633 
 634 
Transit times were measured and scored as described previously (3) using a T1 635 
weighted 3D FFE sequence (TE/TR = 1.5/3.8 ms, FA = 10o, FOV= 250 x 371x 200 636 
mm3) and the ascending and descending colon relaxation times were acquired using 637 
a single slice bTFE sequence. T1 data were acquired with a preparatory 180o 638 
inversion pulse at 8 different inversion times (TI) ranging from 100 – 5000 ms (4), 639 
while T2 data were obtained with a preparatory spin echo pulse before acquiring from 640 
10 different echo times (TE) ranging from 20 – 637 ms (5). For both sequences, 641 
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there was a 10 second gap between each acquisition to allow the system to return to 642 
equilibrium. Small regions of interest were drawn on the resulting images to calculate 643 
the mean signal intensity for the region at each different TI or TE at the top, middle 644 
and bottom of the colonic segments. The relaxation times were determined by fitting 645 
the signal intensity data to a model of the signal evolution of the tissue after 646 
application of all the preparation and imaging radio-frequency pulses. 647 
 648 
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TABLES 668 
Table 1: Variables measured on fasting MRI after 5 days treatment 669 
Median  
(Q25-Q75)  
CONTROLS 
 
PATIENTS † 
Maltodextrin Psyllium 10.5g/d Psyllium 21g/d Maltodextrin n = 9 Psyllium n = 11 
WAPS24 (transit)   1.0 (0.1 – 2.2)   1.4 (0.2 – 2.1)   0.6 (0 – 1.9)     4.2 (3.2 – 5.3)+       2.0 (1.5 – 4.0) 
Small Bowel  
Water Content (mL) 
   51 (15 – 75)    58 (15 – 138)    47 (42 – 157) 33 (9 – 90)    54 (24 – 77)   
Relaxation  
times (ms)  
  
T1AC 720 (572 – 904) 690 (594 – 911) 966 (667 – 1093) 509 (472 – 670)+   890 (478 – 1030) 
T1DC 440 (352 – 884) 570 (473 – 700) 763 (575 – 985) 213 (176 – 420)+  590 (446 – 1338)** 
T2AC    70 (56 – 79)   73 (62 – 86)   83 (67 – 88)   58 (42 – 73)      72 (51 – 105)  
T2DC   53 (40 – 67)   54 (45 – 70)   74 (56 – 80)   42 (34 – 52)     66 (54 – 86)** 
Colon  
Volume (mL) 
  
AC 138 (114 – 208) 213 (152 – 285)* 251 (191 – 301)** 270 (174 – 361)+   390 (320 – 412) 
TC 132 (99 – 188) 
215 (119 – 
332)** 
228 (163 – 362)** 362 (221 – 438)++   366 (267 – 547) 
DC 111 (60 – 185) 142 (117 – 213) 132 (87 – 225) 221 (130 – 278)   246 (221 – 336) 
Total  372 (284 – 601) 
559 (411 – 
807)** 
578 (510 – 882)** 831 (745 – 934)++   1104 (847 – 1316)*  
WAPS24 = weighted averaged position score at 24 hours(15). AC = ascending colon; TC = transverse colon; DC = descending colon. 
 † ITT analysis 
Within-group comparison to maltodextrin *P<0.05; **P<0.01; ***P<0.001.  
Between-groups comparison (controls vs. patients) of maltodextrin results  +P<0.05, ++P<0.01 
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 670 
Table 2: Area Under the Curve of variables measured on postprandial MRI scans during day 6 of treatment 671 
 672 
Median  
(Q25-Q75)  
or Mean (SEM)  
 CONTROLS 
 
PATIENTS † 
Maltodextrin Psyllium 10.5g/d Psyllium 21g/d Maltodextrin n = 9 Psyllium n = 11 
Free Water  
AUC (L.min) 
   
ACWC  0.2 (0.1 – 0.6) 4.0 (2.4 – 7.0)** 7.4 (2.8 – 16.5)** 0.13 (0.01 – 0.66)   3.41 (0.10 – 7.69) 
SBWC 21.3 (12.9 – 33.7) 28.7 (25.2 – 64.5)** 46.5 (37.0 – 82.8)** 13.2 (7.2 – 24.3)  42.8 (24.0 – 49.1)* 
Relaxation times 
AUC (s.min)  
  
T1AC  215 ± 18    303 ± 18 *   374 ± 23***   247 (205 – 306)  411 (265 – 513)*  
T1DC 160 ± 15 188 ± 17 277 ± 35*   94 (76 – 211)  275 (210 – 377) 
T2AC    21 ± 2 30 ± 1**     38 ± 2**** 25 (20 – 30)  34 (32 – 50)  
T2DC 17 (13 – 22) 18 (16 – 22) 24 (20 – 25) 18 (16 – 22)  25 (24 – 29)  
AC = ascending colon; TC = transverse colon; DC = descending colon. WC = water content 
Units of area under the curve expressed as function of time, either litre.minutes or, for relaxation times, second.minutes 
† ITT analysis 
All comparisons to Maltodextrin *p < 0.05; ** p< 0.01; ***p<0.0005  ; ****p<0.0001   
Comparisons by  Wilcoxon signed rank test or paired t-test 
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Supplementary Table 1: Paired analysis of patient data 673 
Paired analysis of fasting and post-prandial MRI variables from patients who undertook treatment periods of both psyllium 7g t.d.s. 674 
and placebo (maltodextrin) 7g t.d.s. for 6 days (n = 16). 675 
676 
Median  
(Q25-Q75)  
or Mean (SEM)  
FASTING  POST-PRANDIAL 
Maltodextrin Psyllium 21g/d  Maltodextrin  Psyllium 
WAPS24     3.4 (1.6 – 4.8)+     2.2 (1.5 – 3.0)  
SBWC 32 (11 – 71) 32 (15 – 60) SBWC (L.min) 13.8 ± 1.8 34.2 ± 4.3 *** 
Colonic  
Volume (mL) 
745 (455 – 844)++ 951 (849 – 1233)*** ACWC (L.min) 0.02 (0.001 – 0.1)  1.13 (0.3 – 7.4)** 
AC 241 (173 – 296)+ 370 (260 – 415)** 
 TC 242 (152 – 372)++ 404 (287 – 537)** 
DC 173 (116 – 218) 232 (217 – 320)** 
Relaxation  
times (ms)  
 
Relaxation times 
AUC (s.min)  
 
T1AC 550 (492 – 609) 820 (440 – 1136)* T1AC   232.8 ± 14.8 386.3 ± 35.8 **    
T1DC 230 (187 – 549)+ 566 (319 – 778)** T1DC   143.3 ± 23.1 247.6 ± 30.3 *** 
T2AC    62 (45 – 70)   72 (54 – 94)* T2AC  25.5 ± 1.0 36.8 ± 2.8 ** 
T2DC   44 (38 – 58)   58 (50 – 67) T2DC 19.6 ± 1.0 23.7 ± 1.1 *** 
WAPS24 = weighted averaged position score at 24 hours(15). AC = ascending colon; TC = transverse colon; DC = descending colon. 
Within-group comparison to maltodextrin *P<0.05; **P<0.01; ***P<0.001 (two-tailed).  
Between-groups comparison (controls vs. patients) of maltodextrin results  +P<0.05, ++P<0.01 
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FIGURE LEGENDS 
Figure 1: Schematic of events during each treatment period. 
Each such period was separated by a washout period of at least one week in the 
control study. In the patient study, subjects additionally recommenced usual laxative 
use for at least 10 days, followed by 8 days off laxatives prior to each study 
treatment. 
 
Figure 2: Changes in MRI parameters of volume and transit. 
A & B) Small bowel water content during a study day in A) controls, B) patients 
treated with placebo (maltodextrin 7 g), psyllium 3.5 g or psyllium 7 g three time 
daily. Ingestion of doses marked by an arrow .  
C) Fasting colonic volume after 5 days treatment.  
D) WAPS24 transit score after 5 days treatment. Higher scores reflect slower transit.   
 
Figure 3: Changes in ascending colon content in response to 5 days psyllium  
A) Single shot balanced gradient echo sequence (bTFE/ TrueFISP) showing 
increase in fasting volume in one patient after 5 days treatment with psyllium 7 g 
t.d.s compared to maltodextrin placebo. 
B) Heavily T2-weighted single shot fast spin sequence (RARE/ SSFSE) showing 
excess colonic water content in one patient after 5 days treatment with psyllium 7 g 
t.d.s compared to maltodextrin placebo. 
 
Figure 4: changes in MRI relaxometry parameters  
  
Major 40 
A) T1 of the chyme in the ascending colon and descending colon after 5 days 
treatment. 
B & C) T1 of the ascending colon during a study day in B) controls, C) patients 
treated with placebo (maltodextrin 7 g), psyllium 3.5 g or psyllium 7 g t.d.s. Ingestion 
of doses marked by an arrow .  
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Figure 5: changes in stool frequency and form 
A) Mean stools frequency for patients during 6-day run-in periods (baseline) and 6 
days on treatment with maltodextrin placebo or 21g/day psyllium 
B) Mean stool consistency according to the Bristol Stool Form Scale 
 
Figure 6: Correlations of relaxometry with fecal water content and stool 
frequency 
A) Fasting T1 relaxometry of descending colon content (T1DC) plotted against fecal 
water content measured by freeze drying, in controls and patients after 5 days 
treatment with maltodextrin placebo.  
B) Mean stool frequency plotted against fasting T1 relaxometry of descending colon 
content (T1DC) 
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